A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/17285598

Cancer 2007 Mar 1 109 5 924-32

Download in:

View as

Triples

General Info

PMID
17285598